GBM Clinical Trials
Here are the 6 most popular medical studies for gbm
Monoclonal Antibodies
Bevacizumab for Glioblastoma
This trial is testing if repeated doses of the cancer drug Bevacizumab, delivered directly to the brain through the artery, is safe and effective in treating newly diagnosed patients with the most aggressive type of brain tumor, glioblastoma multiforme.
Tyrosine Kinase Inhibitor
Lapatinib/Temozolomide/Radiation for Glioblastoma
This trial is for patients with newly diagnosed glioblastoma multiforme. The standard treatment for this cancer is radiation therapy and the chemotherapy agent Temozolomide. However, the study drug Lapatinib has not been FDA approved for use in brain tumor treatment. This study is testing to see if Lapatinib is safe and effective when given in combination with radiation therapy and Temozolomide.
Popular filter options for gbm trials
GBM Clinical Trials
View 93 GBM medical studies.
Monoclonal Antibodies
Bevacizumab + Temozolomide for Glioblastoma and Gliosarcoma
This trial is studying bevacizumab and temozolomide to see how well they work compared to temozolomide alone in treating patients with glioblastoma multiforme or gliosarcoma that has come back or does not respond to treatment.
Histone Deacetylase Inhibitor
Vorinostat + Isotretinoin + Temozolomide for Glioblastoma
This trial is testing if vorinostat, given with isotretinoin and temozolomide, can help control glioblastoma or gliosarcoma. The safety of the drug combination will also be studied.
Dendritic cell immunotherapy
Dendritic Cell Therapy for Glioblastoma
This trial is testing a new therapy, DCVax-L, for patients with newly diagnosed Glioblastoma (GBM) who are scheduled for surgery. The patients will receive the standard of care, including radiation and Temodar therapy, and then will be randomly assigned to also receive either DCVax-L or a placebo. All patients will have the option to receive DCVax-L after their disease progresses.
ATR Kinase Inhibitor
Adavosertib + Radiation Therapy + Temozolomide for Glioblastoma
This trial is studying adavosertib given with radiation therapy and temozolomide to see how well it works compared to radiation therapy and temozolomide alone in treating patients with newly diagnosed or recurrent glioblastoma.
Gliosarcoma Clinical Trials
View 35 Gliosarcoma medical studies.
Monoclonal Antibodies
Bevacizumab + Temozolomide for Glioblastoma and Gliosarcoma
This trial is studying bevacizumab and temozolomide to see how well they work compared to temozolomide alone in treating patients with glioblastoma multiforme or gliosarcoma that has come back or does not respond to treatment.
Chemotherapy
CTO + Temodar® + Radiation Therapy for Glioblastoma and Malignant Gliomas
This trial is testing the safety and effectiveness of a new cancer drug, carboxyamidotriazole orotate (CTO). It will be given alone or in combination with other drugs to patients with brain tumors.
Dendritic cell immunotherapy
Dendritic Cell Therapy for Glioblastoma
This trial is testing a new therapy, DCVax-L, for patients with newly diagnosed Glioblastoma (GBM) who are scheduled for surgery. The patients will receive the standard of care, including radiation and Temodar therapy, and then will be randomly assigned to also receive either DCVax-L or a placebo. All patients will have the option to receive DCVax-L after their disease progresses.
MGMT Positive Clinical Trials
View 15 MGMT positive medical studies.
Monoclonal Antibodies
Nivolumab for Glioblastoma
This trial is comparing the effectiveness of two different drugs to treat brain cancer. One drug is given alone, and the other is given with another drug. The trial will also look at the side effects of the drugs.
PD-1 Positive Clinical Trials
View 6 PD-1 positive medical studies.
CAR T-cell Therapy
Tumor Infiltrating Lymphocytes Immunotherapy for Metastatic Cancer
This trial is testing a new experimental therapy to see if it can cause tumors to shrink in people with digestive tract, urothelial, breast, or ovarian/endometrial cancers. The therapy involves taking white blood cells from patients' tumors, growing them in the laboratory, and then giving the cells back to the patient.
Immune Checkpoint Inhibitor
Retifanlimab + Epacadostat + Radiation + Bevacizumab for Brain Tumor
This trial will test a combination of drugs and radiation therapy to treat glioblastoma. The investigators hope that this will produce a more robust anti-tumor immune response and improve overall survival.
Phase 3 Glioblastoma Clinical Trials
View 96 phase 3 glioblastoma medical studies.
Dendritic cell immunotherapy
Dendritic Cell Therapy for Glioblastoma
This trial is testing a new therapy, DCVax-L, for patients with newly diagnosed Glioblastoma (GBM) who are scheduled for surgery. The patients will receive the standard of care, including radiation and Temodar therapy, and then will be randomly assigned to also receive either DCVax-L or a placebo. All patients will have the option to receive DCVax-L after their disease progresses.
Monoclonal Antibodies
Nivolumab for Glioblastoma
This trial is comparing the effectiveness of two different drugs to treat brain cancer. One drug is given alone, and the other is given with another drug. The trial will also look at the side effects of the drugs.
Glioblastoma Clinical Trials With No Placebo
View 96 glioblastoma medical studies that do not have a placebo group.
CAR T-cell Therapy
Tumor Infiltrating Lymphocytes Immunotherapy for Metastatic Cancer
This trial is testing a new experimental therapy to see if it can cause tumors to shrink in people with digestive tract, urothelial, breast, or ovarian/endometrial cancers. The therapy involves taking white blood cells from patients' tumors, growing them in the laboratory, and then giving the cells back to the patient.
Monoclonal Antibodies
Bevacizumab + Temozolomide for Glioblastoma and Gliosarcoma
This trial is studying bevacizumab and temozolomide to see how well they work compared to temozolomide alone in treating patients with glioblastoma multiforme or gliosarcoma that has come back or does not respond to treatment.
Chemotherapy
CTO + Temodar® + Radiation Therapy for Glioblastoma and Malignant Gliomas
This trial is testing the safety and effectiveness of a new cancer drug, carboxyamidotriazole orotate (CTO). It will be given alone or in combination with other drugs to patients with brain tumors.
Histone Deacetylase Inhibitor
Vorinostat + Isotretinoin + Temozolomide for Glioblastoma
This trial is testing if vorinostat, given with isotretinoin and temozolomide, can help control glioblastoma or gliosarcoma. The safety of the drug combination will also be studied.
View More Gbm Trials
See another 66 many medical studies focused on gbm.
Frequently Asked Questions
Introduction to gbm
What are the top hospitals conducting gbm research?
When it comes to cutting-edge clinical trials for glioblastoma (gbm), several renowned hospitals are leading the charge. One such institution is the Dana-Farber Cancer Institute in Boston, which currently has 17 active gbm trials underway. Glioblastoma, a highly aggressive and deadly form of brain cancerr glioblastoma (gbm), several renowned hospitals are leading the charge. One such institution is the Dana-Farber Cancer Institute in Boston, which currently has 17 active gbm trials underway. Glioblastoma, a highly aggressive and deadly form of brain cancer, poses significant challenges for patients and researchers alike. Likewise, Washington University School of Medicine in Saint Louis is also making strides with 14 ongoing gbm trials of their own. Memorial Sloan Kettering Cancer Center in New York follows closely behind with 13 active gbm trials. These institutions bring together top medical professionals and scientists who work tirelessly to find new treatment options and improve outcomes for those affected by this devastating disease.
Meanwhile, Johns Hopkins University/Sidney Kimmel Cancer Center in Baltimore joins this league with ten ongoing clinical trials specifically focused on glioblastoma research. Last but not least, the Moffitt Cancer Center located in Tampa contributes significantly to the fight against gbm as well; they presently have nine active clinical trials dedicated solely to finding innovative solutions for this challenging condition.
While these hospitals might not yet have any completed or all-time recorded gbm trials under their belts, their commitment to pursuing groundbreaking research offers hope to patients worldwide. By pushing boundaries and exploring novel approaches through these ongoing studies, these institutions play an integral role in advancing our understanding and management of glioblastoma—a crucial step toward improved treatments and ultimately a potential cure that could transform countless lives impacted by this formidable disease.
Which are the best cities for gbm clinical trials?
When it comes to gbm clinical trials, several cities emerge as leading hubs for research and development. Boston, Massachusetts leads the pack with 56 active trials investigating treatments like Ipilimumab, Adavosertib, and others. New York, New York closely follows with 48 ongoing studies focusing on INO-5401, VAL-083, and more. Los Angeles, California is another prominent city in the field with 44 active trials exploring Veliparib and other interventions. Saint Louis, Missouri and Baltimore Maryland also contribute significantly to gbm clinical trials with 27 and 26 active studies respectively. These cities provide individuals battling glioblastoma multiforme, Massachusetts leads the pack with 56 active trials investigating treatments like Ipilimumab, Adavosertib, and others. New York, New York closely follows with 48 ongoing studies focusing on INO-5401, VAL-083, and more. Los Angeles, California is another prominent city in the field with 44 active trials exploring Veliparib and other interventions. Saint Louis, Missouri and Baltimore Maryland also contribute significantly to gbm clinical trials with 27 and 26 active studies respectively. These cities provide individuals battling glioblastoma multiforme access to cutting-edge research that may lead to groundbreaking advancements in treatment options.
Which are the top treatments for gbm being explored in clinical trials?
Glioblastoma multiforme (GBM) remains a challenging disease to treat, but ongoing clinical trials offer hope for patients. Among the top treatments being explored are:
- Temozolomide: Currently involved in 8 active GBM trials and has been widely studied with over 260 all-time trials.
- Bevacizumab: Showing promise in its role as an anti-angiogenic therapy, it is being investigated in 7 active GBM trials and has accumulated over 150 all-time studies.
- Lomustine: With involvement in 5 active GBM trials and over 130 all-time studies, this alkylating agent continues to be explored for its potential benefits. These three treatments represent some of the leading avenues of research that could potentially revolutionize the management of GBM.
What are the most recent clinical trials for gbm?
Recent clinical trials have brought new hope for patients with glioblastoma (gbm), a challenging form of brain cancer. Among these trials, NanO2TM in Phase 2 has shown promise as a potential treatment option. Another study in Phase 3 investigated the combination of radiation therapy (RT) with temozolomide (TMZ) and enzastaurin (ENZ), as well as ENZ alone or TMZ and ENZ, offering potential advancements in gbm treatment approaches. Furthermore, an innovative trial using human CMV pp65-LAMP mRNA-pulsed autologous dendritic cells aims to harness the power of immunotherapyf brain cancith glioblastoma (gbm), a challenging form of brain cancer. Among these trials, NanO2TM in Phase 2 has shown promise as a potential treatment option. Another study in Phase 3 investigated the combination of radiation therapy (RT) with temozolomide (TMZ) and enzastaurin (ENZ), as well as ENZ alone or TMZ and ENZ, offering potential advancements in gbm treatment approaches. Furthermore, an innovative trial using human CMV pp65-LAMP mRNA-pulsed autologous dendritic cells aims to harness the power of immunotherapy against gbm. These recent developments offer renewed optimism for patients fighting this aggressive disease.
What gbm clinical trials were recently completed?
Recently completed clinical trials for glioblastoma (GBM), a highly aggressive form of brain cancerr glioblastoma (GBM), a highly aggressive form of brain cancer, have made significant strides in advancing treatment options. One notable trial focused on the investigation of Uproleselan, led by Washington University School of Medicine and concluded in October 2021. Another groundbreaking study sponsored by the National Cancer Institute examined the efficacy of mRNA-1273 and finished its research phase in September 2021. Lastly, AgenTus Therapeutics successfully completed their agenT-797 trial in January 2021. These achievements highlight the dedication of researchers to combat GBM and provide hope for patients grappling with this devastating disease.